These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29673111)

  • 21. Epidemiology of triple negative breast cancers.
    Gierach GL; Burke A; Anderson WF
    Breast Dis; 2010; 32(1-2):5-24. PubMed ID: 21965309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
    Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
    Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study.
    Zhang H; Xie P; Li Z; Huang R; Feng W; Kong Y; Xu F; Zhao L; Song Q; Li J; Zhang B; Fan J; Qiao Y; Xie X; Zheng S; He J; Wang K
    Diagn Pathol; 2019 May; 14(1):35. PubMed ID: 31054583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between common risk factors and molecular subtypes in breast cancer patients.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Reproductive Factors on the Risk of Breast Cancer by ER/PR and HER2: A Multicenter Case-Control Study in Northern and Eastern China.
    Xie F; Liu L; Yang H; Liu M; Wang S; Guo J; Yu L; Zhou F; Wang F; Xiang Y; Yu Z; Wang S
    Oncologist; 2022 Feb; 27(1):e1-e8. PubMed ID: 35305101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer.
    Lower EE; Blau R; Gazder P; Stahl DL
    Breast Cancer Res Treat; 1999 Dec; 58(3):205-11. PubMed ID: 10718482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Body size and weight change over adulthood and risk of breast cancer by menopausal and hormone receptor status: a pooled analysis of 20 prospective cohort studies.
    van den Brandt PA; Ziegler RG; Wang M; Hou T; Li R; Adami HO; Agnoli C; Bernstein L; Buring JE; Chen Y; Connor AE; Eliassen AH; Genkinger JM; Gierach G; Giles GG; Goodman GG; Håkansson N; Krogh V; Le Marchand L; Lee IM; Liao LM; Martinez ME; Miller AB; Milne RL; Neuhouser ML; Patel AV; Prizment A; Robien K; Rohan TE; Sawada N; Schouten LJ; Sinha R; Stolzenberg-Solomon RZ; Teras LR; Tsugane S; Visvanathan K; Weiderpass E; White KK; Willett WC; Wolk A; Zeleniuch-Jacquotte A; Smith-Warner SA
    Eur J Epidemiol; 2021 Jan; 36(1):37-55. PubMed ID: 33128203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.
    Olsson H; Borg A; Ewers SB; Fernö M; Möller T; Ranstam J
    Med Oncol Tumor Pharmacother; 1986; 3(2):77-81. PubMed ID: 3747639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coffee and tea consumption and risk of pre- and postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study.
    Bhoo-Pathy N; Peeters PH; Uiterwaal CS; Bueno-de-Mesquita HB; Bulgiba AM; Bech BH; Overvad K; Tjønneland A; Olsen A; Clavel-Chapelon F; Fagherazzi G; Perquier F; Teucher B; Kaaks R; Schütze M; Boeing H; Lagiou P; Orfanos P; Trichopoulou A; Agnoli C; Mattiello A; Palli D; Tumino R; Sacerdote C; van Duijnhoven FJ; Braaten T; Lund E; Skeie G; Redondo ML; Buckland G; Pérez MJ; Chirlaque MD; Ardanaz E; Amiano P; Wirfält E; Wallström P; Johansson I; Nilsson LM; Khaw KT; Wareham N; Allen NE; Key TJ; Rinaldi S; Romieu I; Gallo V; Riboli E; van Gils CH
    Breast Cancer Res; 2015 Jan; 17(1):15. PubMed ID: 25637171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk.
    Kampert JB; Whittemore AS; Paffenbarger RS
    Am J Epidemiol; 1988 Nov; 128(5):962-79. PubMed ID: 3189296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.
    Collaborative Group on Hormonal Factors in Breast Cancer
    Lancet Oncol; 2012 Nov; 13(11):1141-51. PubMed ID: 23084519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China.
    Li J; Zhang BN; Fan JH; Pang Y; Zhang P; Wang SL; Zheng S; Zhang B; Yang HJ; Xie XM; Tang ZH; Li H; Li JY; He JJ; Qiao YL
    BMC Cancer; 2011 Aug; 11():364. PubMed ID: 21859480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women.
    de Sousa Almeida-Filho B; De Luca Vespoli H; Pessoa EC; Machado M; Nahas-Neto J; Nahas EAP
    J Steroid Biochem Mol Biol; 2017 Nov; 174():284-289. PubMed ID: 29031688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer in premenopausal and postmenopausal women.
    Stavraky K; Emmons S
    J Natl Cancer Inst; 1974 Sep; 53(3):647-54. PubMed ID: 4412246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Ma H; Ursin G; Xu X; Lee E; Togawa K; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Lu Y; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
    Breast Cancer Res; 2018 Jan; 20(1):5. PubMed ID: 29357906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical information and management status of de novo stage IV breast cancer patients: a Chinese multicenter investigation (CSBrS-002).
    Zheng A; Guo BL; Zhang JG; Jin F;
    Chin Med J (Engl); 2021 Jun; 134(13):1569-1575. PubMed ID: 34101635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes.
    Ding W; Ye D; Chen H; Lin Y; Li Z; Tu C
    Breast Cancer; 2024 Mar; 31(2):295-304. PubMed ID: 38231460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.